A gentle introduction to understanding preclinical data for cancer pharmaco-omic modeling.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 34368843.
- Also identified by DOI 10.1093/bib/bbab312.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A central goal of precision oncology is to administer an optimal drug treatment to each cancer patient. A common preclinical approach to tackle this problem has been to characterize the tumors of patients at the molecular and drug response levels, and employ the resulting datasets for predictive in silico modeling (mostly using machine learning). Understanding how and why the different variants of these datasets are generated is an important component of this process. This review focuses on providing such introduction aimed at scientists with little previous exposure to this research area.
Medical subject headings
- Biomarkers, Tumor
- Computational Biology
- Neoplasms
- Pharmacogenetics